Asthma is one of the most common chronic diseases in the United States and is an important cause of morbidity and mortality, not only in the US, but also worldwide. Over the past decade, obesity has been recognized as an important risk factor for asthma. Epidemiologic studies reveal associations of obesity with the development of asthma, increased risk of asthma exacerbations, and greater risk of hospitalization for asthma. Several studies indicate that conventional asthma therapy has reduced efficacy in obese people with asthma. Our novel preliminary data reveals that signaling through the glucagon-like peptide-1 receptor (GLP- 1R) significantly inhibited lung IL-5 and IL-13 protein and airway eosinophilia in murine in vivo models of both: a) the early innate response prior to the onset of robust adaptive immunity, and b) adaptive immune responses driven by CD4+ Th2 cells. These preliminary data lead us to propose the hypothesis that GLP-1R signaling is a negative regulator of both the early innate and adaptive immune responses in a model of asthma generated by Alternaria airway challenge during high fat diet-induced obesity. This proposal will determine how GLP-1R signaling regulates the activation of host innate immune cells and signaling pathways to the microbial antigens in Alternaria alternata that lead to allergic inflammatory responses in obesity. The proposed studies are paradigm shifting in that they will determine the mechanisms by which GLP-1R signaling: a) inhibits allergen-induced group 2 innate lymphoid cell (ILC2) function and airway epithelial cell IL- 33 production, and b) modulates dendritic cell migration and activation of naive T cells, and T regulatory cell (Treg) function. These proposed studies are clinically relevant in that we will define potential mechanisms by which a GLP-1R agonist, currently FDA approved for the treatment of obesity and diabetes, may be effective in the treatment of allergic airway inflammatory diseases such as asthma in the setting of obesity. The proposed studies will advance the field by defining a novel mechanism that negatively regulates immune responses to the protease containing allergens such as Alternaria alternata in the setting of obesity.

Public Health Relevance

Obesity is becoming an increasingly important risk factor for, and possibly cause of, asthma in the United States. Multiple studies strongly suggest that obese persons with asthma have decreased responsiveness to conventional asthma therapy compared to non-obese people with asthma, imploring the identification of new therapeutic approaches asthma in the setting of obesity. Our preliminary data suggests that glucagon-like peptide 1 receptor (GLP-1R) agonists, a medication class that is currently being used for the treatment of diabetes and also for weight loss, is an important inhibitor of both the early innate and adaptive allergic immune responses.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI124456-05
Application #
10062857
Study Section
Lung Cellular, Molecular, and Immunobiology Study Section (LCMI)
Program Officer
Minnicozzi, Michael
Project Start
2016-12-06
Project End
2021-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
5
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
079917897
City
Nashville
State
TN
Country
United States
Zip Code
37232
Wurth, Mark A; Hadadianpour, Azadeh; Horvath, Dennis J et al. (2018) Human IgE mAbs define variability in commercial Aspergillus extract allergen composition. JCI Insight 3:
Toki, Shinji; Zhou, Weisong; Goleniewska, Kasia et al. (2018) Endogenous PGI2 signaling through IP inhibits neutrophilic lung inflammation in LPS-induced acute lung injury mice model. Prostaglandins Other Lipid Mediat 136:33-43
Bloodworth, Melissa H; Rusznak, Mark; Bastarache, Lisa et al. (2018) Association of ST2 polymorphisms with atopy, asthma, and leukemia. J Allergy Clin Immunol 142:991-993.e3
Celada, Lindsay J; Kropski, Jonathan A; Herazo-Maya, Jose D et al. (2018) PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-?1 production. Sci Transl Med 10:
Tashkin, Donald P; Peebles Jr, R Stokes (2018) Controversies in Allergy: Is Asthma Chronic Obstructive Pulmonary Disease Overlap a Distinct Syndrome That Changes Treatment and Patient Outcomes? J Allergy Clin Immunol Pract :
Stone Jr, Cosby A; Hemler, Jonathan A; Commins, Scott P et al. (2018) Reply. J Allergy Clin Immunol 141:1957-1958
Bloodworth, Melissa H; Rusznak, Mark; Pfister, Connor C et al. (2018) Glucagon-like peptide 1 receptor signaling attenuates respiratory syncytial virus-induced type 2 responses and immunopathology. J Allergy Clin Immunol 142:683-687.e12
Stier, Matthew T; Zhang, Jian; Goleniewska, Kasia et al. (2018) IL-33 promotes the egress of group 2 innate lymphoid cells from the bone marrow. J Exp Med 215:263-281
Stier, Matthew T; Goleniewska, Kasia; Cephus, Jacqueline Y et al. (2017) STAT1 Represses Cytokine-Producing Group 2 and Group 3 Innate Lymphoid Cells during Viral Infection. J Immunol 199:510-519
Stier, Matthew T; Peebles Jr, R Stokes (2017) Innate lymphoid cells and allergic disease. Ann Allergy Asthma Immunol 119:480-488